AChR-Ab Seropositive Generalized Myasthenia Gravis
Immunology·MeSH: Myasthenia Gravis
Prevalence
20.0 / 100K
Incidence
1.7 / 100K/yr
0 drugs in development·0 companies·2 clinical trials
Frequently asked questions
How many clinical trials target AChR-Ab Seropositive Generalized Myasthenia Gravis?
There are 2 clinical trials targeting AChR-Ab Seropositive Generalized Myasthenia Gravis tracked by BioSniper.
What is the prevalence of AChR-Ab Seropositive Generalized Myasthenia Gravis?
The estimated prevalence of AChR-Ab Seropositive Generalized Myasthenia Gravis is approximately 20.0 per 100,000 population.
Deep-dive into AChR-Ab Seropositive Generalized Myasthenia Gravis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis